Distinguished in Type 1 Diabetes (T1D)

Dr. Mark P. Christiansen

Endocrinology
5725 W Las Positas Blvd, #210, 
Pleasanton, CA 
Distinguished in Type 1 Diabetes (T1D)
5725 W Las Positas Blvd, #210, 
Pleasanton, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Christiansen is an Endocrinologist in Pleasanton, California. Dr. Christiansen is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Low Blood Sugar, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and Diabetic Neuropathy.

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 28 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 26 articles and participated in 15 clinical trials in the study of Type 1 Diabetes (T1D).

Specialties
Endocrinology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

5725 W Las Positas Blvd, #210, Pleasanton, CA 94588

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other, Biological
Study Phase: Phase 3
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Biological, Other
Study Drug: Engensis
Study Phase: Phase 3
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Device
Study Phase: Not Applicable
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Device
Study Phase: Not Applicable
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
PROMISE Study: A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza® in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus
DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza® in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: September 18, 2023
Intervention Type: Combination product
Study Phase: Phase 4
Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults
Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Device, Drug
Study Phase: Not Applicable
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Enrollment Status: Completed
Publish Date: June 02, 2023
Intervention Type: Device
Study Phase: Not Applicable
Feasibility Study With Personalized Closed Loop (PCL)
Feasibility Study With Personalized Closed Loop (PCL)
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women With Osteopenia Secondary to Glucocorticoids
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women With Osteopenia Secondary to Glucocorticoids
Enrollment Status: Completed
Publish Date: August 06, 2021
Intervention Type: Drug
Study Drug: LLP2A-Alendronate
Study Phase: Phase 1
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
Enrollment Status: Completed
Publish Date: June 07, 2021
Intervention Type: Device
Study Phase: Not Applicable
User Experience and Daily Use Patterns With the Integrated Insulin Management (IIM) System
User Experience and Daily Use Patterns With the Integrated Insulin Management (IIM) System
Enrollment Status: Completed
Publish Date: January 07, 2021
Intervention Type: Drug, Device
Study Phase: Not Applicable
A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics
Enrollment Status: Withdrawn
Publish Date: September 29, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety
G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety
Enrollment Status: Completed
Publish Date: May 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety
G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
An Early Feasibility Study to Evaluate Basal Initialization Parameters in an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
An Early Feasibility Study to Evaluate Basal Initialization Parameters in an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: April 25, 2019
Intervention Type: Device, Drug
Study Phase: Not Applicable
FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations
FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations
Enrollment Status: Completed
Publish Date: January 28, 2019
Intervention Type: Device
Freestyle Libre Flash Glucose Monitoring System Accuracy Study
Freestyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: November 29, 2018
Intervention Type: Device
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
Enrollment Status: Completed
Publish Date: October 30, 2018
Intervention Type: Drug
Study Phase: Phase 3
Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer
Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer
Enrollment Status: Completed
Publish Date: August 31, 2018
Intervention Type: Device
Study Phase: Not Applicable
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Enrollment Status: Completed
Publish Date: March 20, 2018
Intervention Type: Diagnostic test
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: January 09, 2018
Intervention Type: Device
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: September 06, 2017
Intervention Type: Device
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study
Enrollment Status: Completed
Publish Date: July 11, 2017
Intervention Type: Device
View 26 Less Clinical Trials

38 Total Publications

Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes.
Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes.
Journal: Diabetes technology & therapeutics
Published: March 20, 2025
Similar Doctors
Elite in Type 1 Diabetes (T1D)
Dr. David C. Klonoff
Endocrinology
Elite in Type 1 Diabetes (T1D)
Dr. David C. Klonoff
Endocrinology

University Of California San Francisco

505 Parnassus Ave, 
San Francisco, CA 
 (31.6 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Klonoff is an Endocrinologist in San Francisco, California. Dr. Klonoff is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Low Blood Sugar, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and Diabetic Ketoacidosis.

Elite in Type 1 Diabetes (T1D)
Dr. Marina Basina
Endocrinology
Elite in Type 1 Diabetes (T1D)
Dr. Marina Basina
Endocrinology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (23.7 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marina Basina is an Endocrinologist in Stanford, California. Dr. Basina is rated as a Distinguished provider by MediFind in the treatment of Type 1 Diabetes (T1D). Her top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Papillary Thyroid Cancer, and Hyperthyroidism.

Elite in Type 1 Diabetes (T1D)
Dr. Stephen E. Gitelman
Pediatric Endocrinology | Pediatrics | Endocrinology
Elite in Type 1 Diabetes (T1D)
Dr. Stephen E. Gitelman
Pediatric Endocrinology | Pediatrics | Endocrinology
513 Parnassus Ave, 
San Francisco, CA 
 (31.6 miles away)
415-476-3748
Languages Spoken:
English
See accepted insurances

Stephen Gitelman is a Pediatric Endocrinologist and a Pediatrics provider in San Francisco, California. Dr. Gitelman is rated as an Advanced provider by MediFind in the treatment of Type 1 Diabetes (T1D). His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Obesity, Islet Cell Transplantation, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Christiansen's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile